Vaccination in the peripheral stem cell transplant setting for multiple myeloma: the use of autologous tumor cells with an allogeneic GM-CSF producing cell line

Trial Profile

Vaccination in the peripheral stem cell transplant setting for multiple myeloma: the use of autologous tumor cells with an allogeneic GM-CSF producing cell line

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2005

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor; Tumour cell vaccine-GVAX
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top